IPP Bureau
Kilitch Drugs earmarks Rs. 100 crore as part of its expansion
By IPP Bureau - March 06, 2022
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
Datar Cancer Genetics partners with Kokilaben Hospital to offer advanced cancer tests
By IPP Bureau - March 06, 2022
A simple blood test detects over 30 types of cancers
USFDA approves expanded use of Bristol Myers Opdivo
By IPP Bureau - March 06, 2022
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Healthium collaborates with Abhinav Bindra to treat sports injuries
By IPP Bureau - March 06, 2022
According to an Injury Surveillance Report by NCA last year, 14.75 % of players sustained shoulder injuries, 13.11% of players sustained knee injuries and almost 74 % players suffer from career-threatening Anterior Cruciate Ligament (ACL) injuries in the 1st two years of return to sport
Sir H.N. Reliance Foundation Hospital performs complete robotic gastric bypass surgery
By IPP Bureau - March 06, 2022
Dr. Muffazal Lakdawala performs the largest series of complete robotic gastric bypass surgery in India
Johnson & Johnson Vision Care receives USFDA approval for drug-eluting contact lens
By IPP Bureau - March 06, 2022
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
Aquestive Therapeutics and Haisco Pharmaceutical partner for riluzole in China.
By IPP Bureau - March 06, 2022
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Evonik expands production of plant-derived cholesterol in Germany
By IPP Bureau - March 06, 2022
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
AIkido Pharma improves manufacturing process for pancreatic drug
By IPP Bureau - March 04, 2022
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Oragenics announces positive data on Covid-19 intranasal vaccine
By IPP Bureau - March 04, 2022
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
USFDA issues final guidance on voluntary recalls
By IPP Bureau - March 04, 2022
The guidance also urges companies to act quickly to initiate a recall when public health is at risk and to do so prior to completing an investigation into the cause of the problem
WuXi STA passes EMA drug product pre-approval inspection at its Wuxi City site
By IPP Bureau - March 04, 2022
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
WHO and MPP welcome NIH’s offer of COVID-19 health technologies to C-TAP
By IPP Bureau - March 04, 2022
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
AbbVie acquires Syndesi Therapeutics, strengthening neuroscience portfolio
By IPP Bureau - March 04, 2022
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
New CellScape system for high-plex and high-throughput targeted spatial proteomics
By IPP Bureau - March 04, 2022
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
